Inside the research
Abbott Laboratories
ABT Research profile · latest available data
Price overview
$101.29
▲ +0.22 (+0.2%)
| 52w hi | $131.55 |
|---|---|
| 52w lo | $81.98 |
| Vol | 7.78M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.09
| Short | +0.06 |
|---|---|
| Medium | +0.18 |
| Long | -0.03 |
computed 2026-09-27
Key fundamentals
Abbott Laboratories
Healthcare · Medical Devices
| Market cap | $175.27B |
|---|---|
| Enterprise value | $203.04B |
| Trailing P/E | 32.78x |
| Forward P/E | 16.70x |
| EV / EBITDA | 17.38x |
| P / S (ttm) | 3.79x |
| Profit margin | 11.6% |
| Return on equity | 10.6% |
| Revenue growth | +13.0% |
| Earnings growth | -47.5% |
| Debt / equity | 63.21 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.11 | |
| Sector | +0.08 | |
| Technical | +0.05 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Risk Metrics
| Beta vs SPX | 0.19 |
|---|---|
| Corr SPX | 0.12 |
| Annual vol | 24.5% |
| Annual ret | -2.8% |
| Sharpe | -0.11 |
| Max DD | -41.1% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $118.64 |
|---|---|
| High / Low | $143.00 / $92.00 |
| Median | $120.00 |
| Analysts | 25 |
| Strong Buy | 5 | |
|---|---|---|
| Buy | 16 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-27 | BTIG | → Buy |
| 2026-04-20 | Barclays | → Overweight |
| 2026-04-17 | Stifel | → Buy |
| 2026-04-17 | RBC Capital | → Outperform |
| 2026-04-17 | Piper Sandler | → Overweight |
| 2026-04-17 | Oppenheimer | → Outperform |
Officers & Board
| Director | Michael G. O'Grady since 2023 |
|---|---|
| Director | Claire Babineaux-Fontenot since 2022 |
| Director | Paola Gonzalez since 2021 |
| Director | Mike Roman since 2021 |
| CEO | Robert B. Ford since 2020 |
| Director | Darren W. McDew since 2019 |
| Director | Robert B. Ford since 2019 |
| Director | Michelle Kumbier since 2018 |
| Director | John Stratton since 2017 |
| Director | Daniel Starks since 2017 |
| Director | Sally Blount since 2011 |
| Director | Nancy McKinstry since 2011 |
| Director | Robert Alpern since 2008 |
| Manager | Robert B. Ford current |
| Manager | Miles D. White current |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-16 | Earnings Release, Exhibits | read |
| 2026-04-27 | Officer / Director Change, Bylaws Amendment… | read |
| 2026-04-17 | Other Material Event, Exhibits | read |
| 2026-04-16 | Earnings Release, Exhibits | read |
| 2026-03-23 | Other Material Event, Exhibits | read |
| 2026-03-09 | Material Agreement, Material Obligation… | read |
| 2026-02-26 | Material Agreement, Exhibits | read |
| 2026-02-20 | Bylaws Amendment, Exhibits | read |
| 2026-01-22 | Earnings Release, Exhibits | read |
| 2025-12-12 | Officer / Director Change, Bylaws Amendment… | read |
| 2025-11-21 | 5.04, Exhibits | read |
| 2025-11-20 | Material Agreement, Reg FD Disclosure… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Morrone Louis H. | Officer, EXECUTIVE VICE P | I | 12 | $1.30K |
| 2026-08-11 | Morrone Louis H. | Officer, EXECUTIVE VICE P | Sell | 5.85K | $642.51K |
| 2026-06-30 | Morrone Louis H. | Officer, EXECUTIVE VICE P | Withheld for tax | 269 | $24.94K |
| 2026-06-27 | Cushman Elizabeth C. | Officer, EVP, GC AND SECR | Withheld for tax | 560 | $52.71K |
| 2026-05-07 | Stratton John G | Director | Buy | 2.00K | $173.64K |
| 2026-04-28 | Moreland Mary K | Officer, EXECUTIVE VICE P | I | 5.31K | $501.69K |
| 2026-04-27 | STARKS DANIEL J | Director | Buy | 10.00K | $926.54K |
| 2026-04-24 | O'Grady Michael | Director | Grant | 2.29K | — |
| 2026-04-24 | Roman Michael F | Director | Grant | 2.29K | — |
| 2026-04-24 | Stratton John G | Director | Grant | 2.29K | — |
Flow & Concentration
| Insider 180d net | $658.97K |
|---|---|
| Insider buys / sells | 3 / 1 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 96.1% |
| HHI | 4,394 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $7.34B | 80.93M |
| Fidelity / FMR LLC | $1.22B | 13.42M |
| Citadel Advisors | $1.09B | 12.07M |
| Capital Research / Capital World | $967.52M | 10.66M |
| Millennium Management | $399.75M | 4.41M |
| AQR Capital Management | $380.48M | 4.19M |
| Renaissance Technologies | $62.28M | 686.37K |
| Bridgewater Associates | $5.42M | 59.77K |
| T. Rowe Price Group | $2.07M | 22.79M |
As of 2026-06-30
Dividends
| Yield (TTM) | 1.83% |
|---|---|
| $ / share (TTM) | $1.85 |
| 5y CAGR | +10.4% |
Annual dividend per share
| 2021 | $1.80 |
|---|---|
| 2022 | $1.88 |
| 2023 | $2.04 |
| 2024 | $2.20 |
| 2025 | $2.36 |
| 2026 | $1.26 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $65.47M | Department of Health and Human Services | ABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE |
| $37.60M | Department of Defense | LABORATORY ASSAY FOR TRAUMATIC BRAIN INJURY |
| $12.12M | Department of Veterans Affairs | IGF::OT::IGF CHEMISTRY ANALYZERS/AUTOMATION COST-PER-REPORTABLE RHJ VAMC CHARLES |
| $11.36M | Department of Veterans Affairs | VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE |
| $10.11M | Department of Veterans Affairs | CHEMICAL ANALYZER |
| $9.42M | Department of Veterans Affairs | LAB CHEMISTRY SERVICES |
| $7.09M | Department of Veterans Affairs | VISN 15 CHEMISTRY BPA |
| $6.70M | Department of Defense | CHEMISTRY/IMMUNOASSAY |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $41.95B | +3.1% | |
| Gross profit | $4.40B | -3.3% | |
| Operating income | $6.48B | +0.2% | |
| Net income | $6.52B | +14.8% | |
| Cash from ops | $7.26B | -2.1% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $100.81 | $101.82 | $100.09 | $101.29 | 7.78M |
| Sep 24 | $103.77 | $104.22 | $101.02 | $101.07 | 6.22M |
| Sep 23 | $104.22 | $104.31 | $102.66 | $103.49 | 12.18M |
| Sep 22 | $104.01 | $104.54 | $102.90 | $103.69 | 8.38M |
| Sep 21 | $102.27 | $103.20 | $101.84 | $102.98 | 5.02M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →